Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (PRESERVE)
NCT01486238Phase 4Completed
- Sponsor
- Valley Retina Institute
- Start
- Apr 2009
- Primary completion
- Jul 2011
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pegaptanib sodium in diabetic macular edema (DME) (2 arms), sponsored by Valley Retina Institute. Primary endpoint: Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity (BCVA) Score in the Study Eye Compared With Baseline at 24 weeks. Started Apr 2009; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01486238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486238.